Gao Yi, Fu Shengling, Jiang Wenyang, Li Binfeng, Tian Yitao, Fu Xiangning
Department of Thoracic Surgery, Tongji Hospital, Huazhong University of Science and Technology, Wuhan 430030, China.
Department of Thoracic Surgery, Renmin Hospital, Wuhan University, Wuhan 430060, China.
Zhongguo Fei Ai Za Zhi. 2014 May;17(5):417-23. doi: 10.3779/j.issn.1009-3419.2014.05.10.
Despite undergoing curative resection, the 5-year survival rate for stage III non-small cell lung cancer (NSCLC) patients is less than 25%. There is a need for biomarkers for prediction of survival and guiding individual therapy. MiR-155 is one of most commonly upregulated miRNAs in malignancies, and regulates multiple pro-oncogenic pathways. We aimed to investigate the prognostic impact of miR-155 in resected stage III NSCLC patients.
Tumor formalin-fixed, paraffin-embedded (FFPE) from 162 resected stage III NSCLC patients were collected. Total RNA including miRNA was extracted, and qRT-PCR was used to determine the expression of miR-155.
Spearman rank correlation test showed a positive correlation between miR-155 expression and nodal status (r=0.169, P=0.032). MiR-155 expression had a significant prognostic impact in the total cohort (P<0.001), in squamous cell carcinomas (P=0.002) and in adenocarcinomas (P=0.003). In N0-1 subgroup, miR-155 expression did not have a significant prognostic on overall survival in univariate analysis (P=0.319). In N2 subgroup, miR-155 had a negative prognostic effect on OS in univariate analysis (P<0.001). Cox regression analysis revealed that miR-155 expression was unfavorable prognostic factors of OS (RR=2.311, 95%CI: 1.479-3.611, P<0.001).
High expression of miR-155 represents a valuable marker of poor clinical outcomes in patients with stage III NSCLC.
尽管接受了根治性切除，但Ⅲ期非小细胞肺癌（NSCLC）患者的5年生存率仍低于25%。需要生物标志物来预测生存并指导个体化治疗。MiR-155是恶性肿瘤中最常上调的miRNA之一，可调节多种促癌途径。我们旨在研究MiR-155对Ⅲ期NSCLC切除患者的预后影响。
收集162例Ⅲ期NSCLC切除患者的肿瘤福尔马林固定、石蜡包埋（FFPE）标本。提取包括miRNA在内的总RNA，采用qRT-PCR检测MiR-155的表达。
Spearman等级相关检验显示MiR-155表达与淋巴结状态呈正相关（r=0.169，P=0.032）。MiR-155表达在整个队列（P<0.001）、鳞状细胞癌（P=0.002）和腺癌（P=0.003）中对预后有显著影响。在N0-1亚组中，单因素分析显示MiR-155表达对总生存无显著预后影响（P=0.319）。在N2亚组中，单因素分析显示MiR-155对总生存有负性预后影响（P<0.001）。Cox回归分析显示MiR-155表达是总生存的不良预后因素（RR=2.311，95%CI：1.479-3.611，P<0.001）。
MiR-155高表达是Ⅲ期NSCLC患者临床预后不良的一个有价值的标志物。
